Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients

Launched by UNIVERSITY OF SALAMANCA · Apr 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a special cooling treatment called cryotherapy can help prevent eyebrow and eyelash loss, known as madarosis, in women undergoing chemotherapy for breast cancer. Chemotherapy can lead to the loss of hair, which can significantly affect a patient's self-image and quality of life. In this trial, women diagnosed with breast cancer who are about to start specific types of chemotherapy will receive cryotherapy before and after their treatment to see if it helps them keep their eyebrows and eyelashes.

To participate, women must be at least 18 years old, newly diagnosed with breast cancer, and set to begin chemotherapy with certain medications. They should not have had any previous cancer treatments or hair loss before starting the study. Participants can expect to undergo cryotherapy sessions during their chemotherapy visits, and their hair retention and quality of life will be monitored over time. This trial aims to create a new standard for preventing hair loss during cancer treatment and improve overall patient care.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female participants aged ≥18 years
• • Newly diagnosed breast cancer (any stage)
• • Scheduled to receive anthracycline- and/or taxane-based chemotherapy as first-line systemic treatment
• • No prior history of antineoplastic treatment
• • Willing and able to provide written informed consent
• Exclusion Criteria:
• • Patients with recurrent disease who have received prior hormone therapy, chemotherapy, and/or immunotherapy
• • Presence of alopecia prior to the initiation of cancer treatment
• • History of cerebral radiotherapy